Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 6Completed 4Withdrawn 1Terminated 1Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Gastrointestinal 2Dermatologic 2Gynecologic 1Genitourinary 1CNS 1Breast 1

Conditions

Xeroderma Pigmentosum 1Turcot syndrome 1Neuroblastoma 1Lymphoma 1Hematologic Neoplasms 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Central Nervous System Neoplasms 1

Interventions

Temozolomide 19Magnetic Resonance Spectroscopy 16Radiosurgery 12Bevacizumab 12Radiotherapy 10Radiation 8pembrolizumab 6Specimen Handling 6Methotrexate 6Surgical Procedures, Operative 5Topotecan 4TIC10 compound 4Isotretinoin 4Carmustine 4Carboplatin 4abemaciclib 3Trastuzumab 3Thiotepa 3Standard of Care 3Nivolumab 3Magnetic Resonance Imaging 3Lomustine 3Irinotecan 3Erlotinib Hydrochloride 3Drug Therapy 3Dexamethasone 3vandetanib 2thymoglobulin 2temsirolimus 2pazopanib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × CTLA-4 Antigen × CNS × Clear all
NCT04500548 2025-09-10

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

National Cancer Institute (NCI)

Phase 1 Withdrawn
CNSGastrointestinalLymphoidOther hematologic neoplasm

Turcot syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Lymphoma, Neuroblastoma, Xeroderma Pigmentosum, Central Nervous System Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡